These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 6831472)

  • 1. Effect of pretreatment with phenobarbital or SKF 525A on the toxicity and antitumor activity of lomustine.
    Siemann DW
    Cancer Treat Rep; 1983 Mar; 67(3):259-65. PubMed ID: 6831472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069.
    Siemann DW; Alliet K; Maddison K; Wolf K
    Cancer Treat Rep; 1985 Dec; 69(12):1409-14. PubMed ID: 3841024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of phenobarbital and high doses of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the treatment of brain tumor-bearing mice.
    Muller PJ; Tator CH; Bloom ML
    Cancer Res; 1983 May; 43(5):2068-71. PubMed ID: 6831437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
    Mulcahy RT; Siemann DW
    Cancer Res; 1983 Oct; 43(10):4709-13. PubMed ID: 6883329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole.
    Siemann DW; Morrissey S; Wolf K
    Cancer Res; 1983 Mar; 43(3):1010-3. PubMed ID: 6825075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo interaction between radiation and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the absence or presence of misonidazole in mice.
    Siemann DW; Maddison K; Wolf K; Hill SA; Keng PC
    Cancer Res; 1985 Jan; 45(1):198-202. PubMed ID: 3965132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
    Siemann DW
    Br J Cancer; 1982 Feb; 45(2):272-81. PubMed ID: 6460517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo combination of misonidazole and the chemotherapeutic agent CCNU.
    Siemann DW
    Br J Cancer; 1981 Mar; 43(3):367-77. PubMed ID: 7225287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in the toxicity and antitumor activity of methyl-CCNU in mice following pretreatment with either phenobarbital or SKF 525A.
    Klubes P; Miller HG; Cerna I; Trevithick J
    Cancer Treat Rep; 1979; 63(11-12):1901-7. PubMed ID: 526922
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.
    Workman P; Twentyman PR
    Br J Cancer; 1982 Aug; 46(2):249-59. PubMed ID: 7150475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of secalonic acid D with phenobarbital, 3-methyl cholanthrene, and SKF-525A in mice.
    Reddy CS; Reddy RV; Hayes AW
    J Toxicol Environ Health; 1983; 12(4-6):687-94. PubMed ID: 6668617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in tissue distribution of chlordecone (kepone) in the rat following phenobarbital or SKF-525A administration.
    Aldous CN; Chetty CS; Desaiah D
    J Toxicol Environ Health; 1983 Mar; 11(3):365-72. PubMed ID: 6188850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU.
    Levin VA; Stearns J; Byrd A; Finn A; Weinkam RJ
    J Pharmacol Exp Ther; 1979 Jan; 208(1):1-6. PubMed ID: 759602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased therapeutic benefit through the addition of misonidazole to a nitrosourea-radiation combination.
    Siemann DW; Hill SA
    Cancer Res; 1986 Feb; 46(2):629-32. PubMed ID: 3940631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of combination chemotherapy by nitroheterocyclics.
    Siemann DW; Allalunis-Turner MJ
    Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):129-34. PubMed ID: 3391809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemopotentiation in vivo: no loss of sensitization with fractionation.
    Hill SA; Siemann DW
    Br J Cancer; 1984 Oct; 50(4):509-17. PubMed ID: 6487517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect in the KHT sarcoma of CCNU and MISO on cell cycle progression evaluated by flow-cytometry.
    Hill SA; Bauer KD; Keng PC; Siemann DW
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1619-22. PubMed ID: 6480450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinations of CCNU, MISO, and fractionated radiotherapy.
    Siemann DW; Alliet KL
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1379-82. PubMed ID: 3759559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced tumor responses through therapies combining CCNU, MISO and radiation.
    Siemann DW; Hill SA
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1623-6. PubMed ID: 6480451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methyl-CCNU: preclinical toxicologic evaluation of a single iv infusion in dogs and monkeys.
    Schaeppi U; Fleischman RW; Phelan RS; Ethier MF; Luthra YK
    Cancer Treat Rep; 1976 Oct; 60(10):1559-66. PubMed ID: 828519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.